TRD205

Phase 2Small molecule

BBeijing Tide Pharmaceutical Co., Ltd

TRD205 is one of 45 small molecule programs targeting Hallux valgus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hallux ValgusActive, not recruiting

NeuralgiaActive, not recruiting

Hallux ValgusPhase 1

Active, not recruiting

NeuralgiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

46 competitors in Neuralgia

#DrugCompanyPhaseTrials

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

5 2

Cymbalta

Alnylam Pharmaceuticals

Xylocaine

3 4

Marcaine

IInnocoll

Approved

1 5

Aspercreme Warming

AAveritas Pharma, Inc.

Approved

—6

Fycompa

CCatalyst Biosciences

Approved

—7

Aptiom

Sumitomo Pharma America, Inc.

Phase 3

2 8

Neurontin

VViatris Specialty LLC

Phase 3

2 9

Decadron

AAspen Global Incorporated

Phase 3

1 10

Valtrex

GGlaxo Dba Glaxosmithkline

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hallux valgus1 trial

To Evaluate the Safety, Efficacy and Kinetic Characteristics of TRD205 Tablets for Postoperative Analgesia After Unilateral Hallux Valgus Orthopedic Surgery

Not yet recruiting·BBeijing Tide Pharmaceutical Co., Ltd·Phase 1·NCT07121023·32 enrolled

Postoperative Analgesia After Unilateral Hip Arthroplasty1 trial

To Evaluate the Safety, Efficacy and Kinetic Characteristics of TRD205 Tablets for Postoperative Analgesia After Unilateral Hip Arthroplasty

Not yet recruiting·BBeijing Tide Pharmaceutical Co., Ltd·Phase 2·NCT07121101·40 enrolled

Neuralgia1 trial

To Evaluate the Efficacy and Safety of TRD205 Tablets in the Treatment of Chronic Postoperative Neuralgia

Enrolling by invitation·BBeijing Tide Pharmaceutical Co., Ltd·Phase 2·NCT07123402·184 enrolled

Unspecified1 trial

Single and Multiple Ascending Doses and Food Effect Study of TRD205 in Healthy Volunteers

Completed·BBeijing Tide Pharmaceutical Co., Ltd·Phase 1·NCT07123428·151 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for TRD205. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TRD205 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TRD205. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Tide Pharmaceutical Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBeijing Tide Pharmaceutical Co., Ltd

TRD205

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hallux valgus1 trial

Postoperative Analgesia After Unilateral Hip Arthroplasty1 trial

Neuralgia1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News